Intelligence · Clinical Development
Pipeline search results
Programs matching “Novartis” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 341 pipeline programs matching "Novartis" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
CYTB323L12201
Novartis Pharmaceuticals
Severe refractory idiopathic inflammatory myopathies (IIM)
1 trial -
CYTB323M12101B
Novartis Pharmaceuticals
Difficult to treat rheumatoid arthritis, Severe, refractory Sjogren’s disease with organ involvement
1 trial -
CYTB323N12101
Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
1 trial -
CYTB323O12101
Novartis Pharmaceuticals
Treatment-resistant generalized Myasthenia Gravis
1 trial -
CYTB323R12101
Novartis Pharmaceuticals
Non-active Progressive Multiple Sclerosis (PMS)
1 trial -
Canakinumab 150 mg
Novartis Pharmaceuticals
Type 2 Diabetes Mellitus
1 trial -
Capecitabine
Novartis Pharmaceuticals
Breast Cancer
1 trial -
Ceritinib (LDK378)
Novartis Pharmaceuticals
Tumors With Aberrations in ALK
1 trial -
DYP688
Novartis Pharmaceuticals
Metastatic uveal melanoma, other GNAQ/11 mutant melanomas (e.g. skin or mucosal melanoma)
1 trial -
Dabrafenib
Novartis Pharmaceuticals
Cancer
1 trial -
Deferasirox
Novartis Pharmaceuticals
Myelodysplastic Syndromes
1 trial -
Deferasirox granule formulation
Novartis Pharmaceuticals
Transfusion-dependent Anemia
1 trial -
EYU688
Novartis Pharmaceuticals
Dengue
1 trial -
Eltrombopag
Novartis Pharmaceuticals
Aplastic Anemia
1 trial -
FGF401
Novartis Pharmaceuticals
Hepatocellular Carcinoma (HCC)
1 trial -
GIA632
Novartis Pharmaceuticals
Atopic Dermatitis
1 trial -
HCD122
Novartis Pharmaceuticals
Non-Hodgkin's Lymphoma
1 trial -
INC280
Novartis Pharmaceuticals
Non-small Cell Lung Cancer
1 trial -
Iptacopan
Novartis Pharmaceuticals
Immune Thrombocytopenia (ITP)
1 trial -
JDQ443
Novartis Pharmaceuticals
Locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression ≥ 1% and an STK11 co-mutation.
1 trial -
KAE609
Novartis Pharmaceuticals
Malaria
1 trial -
KAE609
Novartis Pharmaceuticals
Cure Rate
1 trial -
KAF156
Novartis Pharmaceuticals
Acute Uncomplicated Plasmodium Falciparum Malaria
1 trial -
KAF156
Novartis Pharmaceuticals
Malaria
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.